Abstract
Cetobacterium somerae, a gram-negative anaerobic rod, first identified in the feces of children with autism,
also colonize freshwater fish intestinal tract. However there have been no reports
of human C. somerae infection. Here, we describe the first case of C. somerae bacteremia in a patient with necrotizing cholecystitis. A 72-year-old male presented
to the emergency department with chills, vomiting, and fever and was diagnosed with
acute necrotizing cholecystitis. An emergency cholecystectomy was performed and the
following day, two sets of blood culture were positive for gram-negative bacilli.
Identification of C. somerae from the biochemical profile was difficult but possible by mass spectrometry and
16s rRNA sequence.
Keywords
Abbreviations:
AST (antimicrobial susceptibility testing), BLAST (Basic Local Alignment Search Tool), BTB (bromothymol blue), CT (computed tomography), GAM (Gifu anaerobic agar medium), MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight mass spectrometry), MIC (minimum inhibitory concentration)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Infection and ChemotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cetobacterium somerae sp. nov. from human feces and emended description of the genus Cetobacterium.Syst Appl Microbiol. 2003; 26: 177-181https://doi.org/10.1078/072320203322346010
- Effect of dietary supplementation of Cetobacterium somerae XMX-1 fermentation product on gut and liver health and resistance against bacterial infection of the genetically improved f armed tilapia (GIFT, Oreochromis niloticus).Fish Shellfish Immunol. 2022; 124: 332-342https://doi.org/10.1016/j.fsi.2022.04.019
- Novel ecological niche of Cetobacterium somerae, an anaerobic bacterium in the intestinal tracts of freshwater fish.Lett Appl Microbiol. 2008; 46: 43-48https://doi.org/10.1111/j.1472-765X.2007.02258.x
- Intestinal Cetobacterium and acetate modify glucose homeostasis via parasympathetic activation in zebrafish.Gut Microb. 2021; 13: 1-15https://doi.org/10.1080/19490976.2021.1900996
- Effects of Cetobacterium somerae fermentation product on gut and liver health of common carp (Cyprinus carpio) fed diet supplemented with ultra-micro ground mixed plant proteins.Aquaculture. 2021; 543736943https://doi.org/10.1016/j.aquaculture.2021.736943
- Host-Microbiota interactions and responses to grass carp reovirus infection in Ctenopharyngodon idellus.Environ Microbiol. 2021; 23: 431-447https://doi.org/10.1111/1462-2920.15330
- Stabilized fermentation product of Cetobacterium somerae improves gut and liver health and antiviral immunity of zebrafish.Fish Shellfish Immunol. 2022; 120: 56-66https://doi.org/10.1016/j.fsi.2021.11.017
- In vitro activity of linezolid against clinical isolates of Fusobacterium spp.J Antimicrob Chemother. 2006; 58: 789-793https://doi.org/10.1093/jac/dkl338
- In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.Antimicrob Agents Chemother. 2013; 57: 2620-2630https://doi.org/10.1128/AAC.02418-12
- Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers, Antimicrob.Agents Chemother. 1990; 34: 1546-1550https://doi.org/10.1128/AAC.34.8.1546
- Tokyo Guideline Revision Committee, TG13 antimicrobial therapy for acute cholangitis and cholecystitis.J. Hepato-Bil. Pancreat. Sci. 2013; 20: 60-70https://doi.org/10.1007/s00534-012-0572-0
- Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis.J. Hepatobiliary. Pancreat. Sci. 2018; 25: 3-16https://doi.org/10.1002/jhbp.518
- Emphysematous cholecystitis secondary to Fusobacterium nucleatum.Cureus. 2021; 13e15660https://doi.org/10.7759/cureus.15660
Article info
Publication history
Published online: May 16, 2023
Accepted:
May 2,
2023
Received in revised form:
April 14,
2023
Received:
February 28,
2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
